Mats Jerkeman

Adjungerad Professor, Överläkare , Sektionschef, Professor, överläkare
Fler filtreringsmöjligheter
  1. 2020
  2. Clonal hematopoiesis evolves from pretreatment clones and stabilizes after end of chemotherapy in patients with MCL

    Eskelund, C. W., Husby, S., Favero, F., Klausen, T. W., Rodriguez-Gonzalez, F. G., Kolstad, A., Pedersen, L. B., Räty, R. K., Geisler, C. H., Mats Jerkeman, Weischenfeldt, J. & Grønbæk, K., 2020 maj 28, I : Blood. 135, 22, s. 2000-2004 5 s.

    Forskningsoutput: TidskriftsbidragLetter

  3. Healthy lifestyle and the risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition study

    Naudin, S., Solans Margalef, M., Saberi Hosnijeh, F., Nieters, A., Kyrø, C., Tjønneland, A., Dahm, C. C., Overvad, K., Mahamat-Saleh, Y., Besson, C., Boutron-Ruault, M. C., Kühn, T., Canzian, F., Schulze, M. B., Peppa, E., Karakatsani, A., Trichopoulou, A., Sieri, S., Masala, G., Panico, S. & 21 andra, Tumino, R., Ricceri, F., Chen, S. L. F., Barroso, L. L., Huerta, J. M., Sánchez, M. J., Ardanaz, E., Menéndez, V., Amiano Exezarreta, P., Spaeth, F., Mats Jerkeman, Karin Jirstom, Schmidt, J. A., Aune, D., Weiderpass, E., Riboli, E., Vermeulen, R., Casabonne, D., Gunter, M., Brennan, P. & Ferrari, P., 2020 mar 30, I : International Journal of Cancer.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  4. Outcome and determinants of failure to complete primary R-CHOP treatment for reasons other than non-response among patients with diffuse large B-cell lymphoma

    Wästerlid, T., Harrysson, S., Andersson, T. M. L., Ekberg, S., Enblad, G., Andersson, P. O., Mats Jerkeman, Eloranta, S. & Smedby, K. E., 2020 mar 17, I : American Journal of Hematology.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  5. Detection of HPV mRNA in Self-collected Vaginal Samples Among Urban Ethiopian Women

    Selamawit Mekuria, Mats Jerkeman, Ola Forslund, Fikru, S. & Christer Borgfeldt, 2020 mar, I : Anticancer research. 40, 3, s. 1513-1517

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  6. Trends in the prevalence, incidence and survival of non-Hodgkin lymphoma subtypes during the 21st century – a Swedish lymphoma register study

    Ekberg, S., E. Smedby, K., Glimelius, I., Nilsson-Ehle, H., Goldkuhl, C., Lewerin, C., Mats Jerkeman & Eloranta, S., 2020 feb 17, I : British Journal of Haematology.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  7. 2019
  8. Comorbidities and sex differences in causes of death among mantle cell lymphoma patients – A nationwide population-based cohort study

    Glimelius, I., Smedby, K. E., Eloranta, S., Mats Jerkeman & Weibull, C. E., 2019 nov 13, I : British Journal of Haematology.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  9. Relapse Risk and Loss of Lifetime After Modern Combined Modality Treatment of Young Patients With Hodgkin Lymphoma: A Nordic Lymphoma Epidemiology Group Study

    Biccler, J. L., Glimelius, I., Eloranta, S., Smeland, K. B., Brown, P. D. N., Jakobsen, L. H., Frederiksen, H., Mats Jerkeman, Fosså, A., Andersson, T. M. L., Holte, H., Bøgsted, M., El-Galaly, T. C. & Smedby, K. E., 2019 mar 20, I : Journal of Clinical Oncology. 37, 9, s. 703-713 11 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  10. Adherence to the mediterranean diet and lymphoma risk in the european prospective investigation into cancer and nutrition

    Solans, M., Benavente, Y., Saez, M., Agudo, A., Naudin, S., Hosnijeh, F. S., Noh, H., Freisling, H., Ferrari, P., Besson, C., Mahamat-Saleh, Y., Boutron-Ruault, M. C., Kühn, T., Kaaks, R., Boeing, H., Lasheras, C., Rodríguez-Barranco, M., Amiano, P., Huerta, J. M., Barricarte, A. & 26 andra, Schmidt, J. A., Vineis, P., Riboli, E., Trichopoulou, A., Bamia, C., Peppa, E., Masala, G., Agnoli, C., Tumino, R., Sacerdote, C., Panico, S., Skeie, G., Weiderpass, E., Mats Jerkeman, Ulrika Ericson, Späth, F., Nilsson, L. M., Dahm, C. C., Overvad, K., Bolvig, A. K., Tjønneland, A., de Sanjose, S., Buckland, G., Vermeulen, R., Nieters, A. & Casabonne, D., 2019, I : International Journal of Cancer. 145, 1, s. 122-131

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  11. Comparison of the NCCN-IPI, the IPI and PIT scores as prognostic tools in peripheral T-cell lymphomas

    Fredrik Ellin, Maurer, M. J., Srour, L., Farooq, U., Mats Jerkeman, Connors, J. M., Smedby, K. E., Bennani, N. N., Ansell, S. M., Slack, G. W., Cerhan, J. R., Relander, T., Feldman, A. L. & Savage, K. J., 2019, I : British Journal of Haematology. 186, 3, s. e24-e27

    Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

  12. Follicular Lymphoma: Recent and Emerging Therapies, Treatment Strategies, and Remaining Unmet Needs

    Matasar, M. J., Luminari, S., Barr, P. M., Barta, S. K., Danilov, A. V., Hill, B. T., Phillips, T. J., Mats Jerkeman, Magagnoli, M., Nastoupil, L. J., Persky, D. O. & Okosun, J., 2019, I : Oncologist.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  13. Impact of comorbidity on disease characteristics, treatment intent and outcome in diffuse large B-cell lymphoma: a Swedish lymphoma register study

    Wästerlid, T., Mohammadi, M., Smedby, K. E., Glimelius, I., M. Jerkeman, Bottai, M. & Eloranta, S., 2019, I : Journal of Internal Medicine. 285, 4, s. 455-468

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  14. Inflammatory potential of diet and risk of lymphoma in the European Prospective Investigation into Cancer and Nutrition

    Solans, M., Benavente, Y., Saez, M., Agudo, A., Jakszyn, P., Naudin, S., Hosnijeh, F. S., Gunter, M., Huybrechts, I., Ferrari, P., Besson, C., Mahamat-Saleh, Y., Boutron-Ruault, M. C., Kühn, T., Kaaks, R., Boeing, H., Lasheras, C., Sánchez, M. J., Amiano, P., Chirlaque, M. D. & 26 andra, Ardanaz, E., Schmidt, J. A., Vineis, P., Riboli, E., Trichopoulou, A., Karakatsani, A., Valanou, E., Masala, G., Agnoli, C., Tumino, R., Sacerdote, C., Mattiello, A., Skeie, G., Weiderpass, E., Mats Jerkeman, Joana Alves Dias, Späth, F., Nilsson, L. M., Dahm, C. C., Overvad, K., Petersen, K. E. N., Tjønneland, A., de Sanjose, S., Vermeulen, R., Nieters, A. & Casabonne, D., 2019, I : European Journal of Nutrition.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  15. Monitoring CAR-T-Cell Therapies Using the Nordic Healthcare Databases

    Callréus, T., El-Galaly, T. C., Mats Jerkeman, de Nully Brown, P. & Andersen, M., 2019, I : Pharmaceutical Medicine. 33, 2, s. 83-88 6 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  16. Reproductive Factors, Exogenous Hormone Use, and Risk of B-Cell Non-Hodgkin Lymphoma in a Cohort of Women From the European Prospective Investigation Into Cancer and Nutrition

    Costas, L., Lujan-Barroso, L., Benavente, Y., Allen, N. E., Amiano, P., Ardanaz, E., Besson, C., Boeing, H., Bueno-de-Mesquita, B., Cervenka, I., Fortner, R. T., Fournier, A., Gunter, M., Harlid, S., Huerta, J. M., Jerkeman, M., Jirström, K., Kaaks, R., Karakatsani, A., Khaw, K. T. & 22 andra, Kotanidou, A., Lund, E., Masala, G., Mattiello, A., Melin, B., Menéndez, V., Murphy, N., Nieters, A., Overvad, K., Riboli, E., Sacerdote, C., Sánchez, M. J., Schmidt, J. A., Sieri, S., Tjønneland, A., Trichopoulou, A., Tumino, R., Vermeulen, R., Weiderpass, E., de Sanjosé, S., Agudo, A. & Casabonne, D., 2019, I : American Journal of Epidemiology. 188, 2, s. 274-281 8 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  17. 2018
  18. A platform for phenotypic discovery of therapeutic antibodies and targets applied on Chronic Lymphocytic Leukemia

    A. Ljungars, Mårtensson, L., Jenny Mattsson, Kovacek, M., Sundberg, A., Tornberg, U-C., B. Jansson, Persson, N., V. Kuci Emruli, S. Ek, M. Jerkeman, M. Hansson, G. Juliusson, M. Ohlin, Frendéus, B., Teige, I. & Mattsson, M., 2018 dec 1, I : JCO Precision Oncology. 2, 1

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  19. Body composition measurements and risk of hematological malignancies: A population-based cohort study during 20 years of followup

    Hagström, H., Andreasson, A., Carlsson, A. C., Mats Jerkeman & Carlsten, M., 2018 aug 23, I : PLoS ONE. 13, 8, e0202651.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  20. Long-term survival and loss in expectancy of life in a population-based cohort of 7114 patients with diffuse large B-cell lymphoma

    Ekberg, S., Mats Jerkeman, Andersson, P. O., Enblad, G., Wahlin, B. E., Hasselblom, S., Andersson, T. M., Eloranta, S. & Smedby, K. E., 2018 aug 1, I : American Journal of Hematology. 93, 8, s. 1020-1028 9 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  21. Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study

    Rule, S., Jurczak, W., M. Jerkeman, Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., Hess, G., Bence-Bruckler, I., Cho, S. G., Thieblemont, C., Zhou, W., Henninger, T., Goldberg, J., Vermeulen, J. & Dreyling, M., 2018 aug, I : Leukemia. 32, 8, s. 1799-1803

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  22. Valproate in combination with rituximab and CHOP as first-line therapy in diffuse large B-cell lymphoma (VALFRID)

    Kristina Drott, Hagberg, H., Papworth, K., Relander, T. & Mats Jerkeman, 2018 jun 26, I : Blood Advances. 2, 12, s. 1386-1392 7 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  23. Bortezomib prevents cytarabine resistance in MCL, which is characterized by down-regulation of dCK and up-regulation of SPIB resulting in high NF-κB activity

    Freiburghaus, C., Venera Kuci Emruli, Johansson, A., Eskelund, C. W., Grønbæk, K., Roger Olsson, Fredrik Ek, Mats Jerkeman & Sara Ek, 2018 apr 25, I : BMC Cancer. 18, 1, 466.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  24. Ibrutinib, lenalidomide, and rituximab in relapsed or refractory mantle cell lymphoma (PHILEMON): A multicentre, open-label, single-arm, phase 2 trial

    Mats Jerkeman, Eskelund, C. W., Hutchings, M., Räty, R., Wader, K. F., Laurell, A., Toldbod, H., Pedersen, L. B., Niemann, C. U., Dahl, C., Kuitunen, H., Geisler, C. H., Grønbæk, K. & Kolstad, A., 2018 mar, I : The Lancet Haematology. 5, 3, s. e109-e116

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  25. Simplicity at the cost of predictive accuracy in diffuse large B-cell lymphoma: A critical assessment of the R-IPI, IPI, and NCCN-IPI

    Biccler, J., Eloranta, S., de Nully Brown, P., Frederiksen, H., Mats Jerkeman, Smedby, K. E., Bøgsted, M. & El-Galaly, T. C., 2018 jan, I : Cancer Medicine. 7, 1, s. 114-122

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  26. Impact of comorbidity on survival in peripheral T-cell lymphomas: A Swedish Lymphoma Registry study

    Fredrik Ellin, Mats Jerkeman, Törnqvist, J., Brudin, L. & Relander, T., 2018, I : Hematological Oncology. 36, 1, s. 159-165

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  27. Lenalidomide plus bendamustine-rituximab does not overcome the adverse impact of TP53 mutations in mantle cell lymphoma

    Eskelund, C. W., Alexandra Albertsson-Lindblad, Kolstad, A., Laurell, A., Räty, R., Pedersen, L. B., Geisler, C. H., Mats Jerkeman & Grønbæk, K., 2018, I : Haematologica. 103, 11, s. e541-e543

    Forskningsoutput: TidskriftsbidragLetter

  28. Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

    Dang, N. H., Ogura, M., Castaigne, S., Fayad, L. E., Mats Jerkeman, Radford, J., Pezzutto, A., Bondarenko, I. N., Stewart, D. A., Shnaidman, M., Sullivan, S., Vandendries, E., Tobinai, K., Ramchandren, R., Hamlin, P. A., Giné, E. & Ando, K., 2018, I : British Journal of Haematology. 182, 4, s. 583-586

    Forskningsoutput: TidskriftsbidragDebate/Note/Editorial

  29. Treatment for patients with relapsed/refractory mantle cell lymphoma: European-based recommendations

    Dreyling, M., Aurer, I., Cortelazzo, S., Hermine, O., Hess, G., Mats Jerkeman, Le Gouill, S., Ribrag, V., Trněný, M., Visco, C., Walewski, J., Zaja, F. & Zinzani, P. L., 2018, I : Leukemia and Lymphoma. 59, 8, s. 1814-1828

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  30. 2017
  31. International Assessment of Event-Free Survival at 24 Months and Subsequent Survival in Peripheral T-Cell Lymphoma

    Maurer, M. J., Fredrik Ellin, Srour, L., Mats Jerkeman, Bennani, N. N., Connors, J. M., Slack, G. W., Smedby, K. E., Ansell, S. M., Link, B. K., Cerhan, J. R., Relander, T., Savage, K. J. & Feldman, A. L., 2017 dec 20, I : Journal of Clinical Oncology. 35, 36, s. 4019-4026 8 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  32. Outcome of peripheral T-cell lymphoma in first complete remission: a Danish-Swedish population-based study

    Henrik Cederleuf, Hjort Jakobsen, L., Fredrik Ellin, de Nully Brown, P., Stauffer Larsen, T., Bøgsted, M., Relander, T., Mats Jerkeman & El-Galaly, T. C., 2017 dec 2, I : Leukemia and Lymphoma. 58, 12, s. 2815-2823 9 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  33. Crosstalk between ROR1 and BCR pathways defines novel treatment strategies in mantle cell lymphoma.

    Karvonen, H., Chiron, D., Niininen, W., Sara Ek, Mats Jerkeman, Moradi, E., Nykter, M., Heckman, C. A., Kallioniemi, O., Murumägi, A. & Ungureanu, D., 2017 nov 9, I : Blood Advances. 1, 24, s. 2257-2268

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  34. TP53 mutations identify younger mantle cell lymphoma patients who do not benefit from intensive chemoimmunotherapy

    Eskelund, C. W., Dahl, C., Hansen, J. W., Westman, M., Kolstad, A., Pedersen, L. B., Montano-Almendras, C. P., Husby, S., Freiburghaus, C., Sara Ek, Pedersen, A., Niemann, C., Raty, R., Brown, P., Geisler, C. H., Andersen, M. K., Guldberg, P., Mats Jerkeman & Grønbæk, K., 2017 okt 26, I : Blood. 130, 17, s. 1903-1910 8 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  35. Frequency and clinical implications of SOX11 expression in Burkitt lymphoma

    Wästerlid, T., Nordström, L., Freiburghaus, C., Pedersen, M., Nørgaard, P., Gang, A. O., Brown, P., Michael Dictor, Mats Jerkeman & Sara Ek, 2017, I : Leukemia & Lymphoma. 58, 7, s. 1760-1763 4 s.

    Forskningsoutput: TidskriftsbidragLetter

  36. Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus

    Hess, G., Rule, S., Jurczak, W., Mats Jerkeman, Santucci Silva, R., Rusconi, C., Caballero, D., Joao, C., Witzens-Harig, M., Bence-Bruckler, I., Cho, S-G., Zhou, W., Goldberg, J. D., Trambitas, C., Enny, C., Vermeulen, J., Traina, S., Chiou, C. F., Diels, J. & Dreyling, M., 2017, I : Leukemia and Lymphoma. 58, 12, s. 2824-2832

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  37. Molecular Monitoring after Autologous Stem Cell Transplantation and Preemptive Rituximab Treatment of Molecular Relapse; Results from the Nordic Mantle Cell Lymphoma Studies (MCL2 and MCL3) with Median Follow-Up of 8.5 Years

    Kolstad, A., Pedersen, L. B., Eskelund, C. W., Husby, S., Grønbæk, K., Jerkeman, M., Laurell, A., Räty, R., Elonen, E., Andersen, N. S., Brown, P. D. N., Kimby, E., Bentzen, H., Sundström, C., Ehinger, M., Karjalainen-Lindsberg, M-L., Delabie, J., Ralfkiær, E., Fagerli, U-M., Nilsson-Ehle, H. & 4 andra, Lauritzsen, G. F., Kuittinen, O., Niemann, C. & Geisler, C. H., 2017, I : Biology of Blood and Marrow Transplantation. 23, 3, s. 428-435

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  38. Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

    Dreyling, M., Campo, E., Hermine, O., M. Jerkeman, Le Gouill, S., Rule, S., Shpilberg, O., Walewski, J., Ladetto, M. & on behalf of the ESMO Guidelines Committee, 2017, I : Annals of Oncology. 28, s. iv62-iv71

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  39. Targeting of B-cell receptor signalling in B-cell malignancies

    M. Jerkeman, Hallek, M., Dreyling, M., Thieblemont, C., Kimby, E. & Staudt, L., 2017, I : Journal of Internal Medicine. 282, 5, s. 415-428

    Forskningsoutput: TidskriftsbidragÖversiktsartikel

  40. The addition of etoposide to CHOP is associated with improved outcome in ALK+ adult anaplastic large cell lymphoma: A Nordic Lymphoma Group study

    Henrik Cederleuf, Bjerregård Pedersen, M., Mats Jerkeman, Relander, T., d'Amore, F. & Fredrik Ellin, 2017, I : British Journal of Haematology. 178, 5, s. 739-746

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  41. 2016
  42. Plasma immunoprofiling of patients with high-risk diffuse large B-cell lymphoma: a Nordic Lymphoma Group study

    Pauly, F., Fjordén, K., Leppä, S., Holte, H., Björkholm, M., Fluge, Møller Pedersen, L., M. Eriksson, A. Isinger-Ekstrand, C. A.K. Borrebaeck, M. Jerkeman & Wingren, C., 2016 nov 18, I : Blood Cancer Journal. 6, 11, s. e501

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  43. Chemotherapeutic intensity and survival differences in young patients with diffuse large B-cell lymphoma: a Swedish Lymphoma Registry study

    Melén, C. M., Enblad, G., Sonnevi, K., Junlén, H. R., Smedby, K. E., Mats Jerkeman & Wahlin, B. E., 2016 nov 1, I : British Journal of Haematology. 175, 4, s. 614-622 9 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  44. Clinical characteristics and outcomes of patients with Hodgkin lymphoma with central nervous system involvement: An international multicenter collaboration

    Cheah, C. Y., Bröckelmann, P. J., Chihara, D., Moskowitz, A. J., Engert, A., Mats Jerkeman, El-Galaly, T. C., Augustson, B., Vose, J., Bartlett, N. L., Villa, D., Connors, J. M., Feldman, T., Pinnix, C. C., Milgrom, S. A., Dabaja, B., Oki, Y. & Fanale, M. A., 2016 sep 1, I : American Journal of Hematology. 91, 9, s. 894-899 6 s.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  45. Lenalidomide-bendamustine-rituximab in untreated mantle cell lymphoma > 65 years, the Nordic Lymphoma Group phase I+II trial NLG-MCL4

    Alexandra Albertsson-Lindblad, Kolstad, A., Laurell, A., Räty, R., Grønbæk, K., Sundberg, J., Pedersen, L. B., Ralfkiær, E., Karjalainen-Lindsberg, M-L., Sundström, C., Mats Ehinger, Geisler, C. & Mats Jerkeman, 2016 jun 27, I : Blood. 128, 14, s. 1814-1820

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  46. 15-year follow-up of the Second Nordic Mantle Cell Lymphoma trial (MCL2): Prolonged remissions without survival plateau

    Eskelund, C. W., Kolstad, A., Jerkeman, M., Räty, R., Laurell, A., Eloranta, S., Smedby, K. E., Husby, S., Pedersen, L. B., Andersen, N. S., Eriksson, M., Kimby, E., Bentzen, H., Kuittinen, O., Lauritzsen, G. F., Nilsson-Ehle, H., Ralfkiær, E., Ehinger, M., Sundström, C., Delabie, J. & 7 andra, Karjalainen-Lindsberg, M. L., Workman, C. T., Garde, C., Elonen, E., Brown, P., Grønbæk, K. & Geisler, C. H., 2016, I : British Journal of Haematology. 175, 3, s. 410-418

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  47. Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study.

    Dreyling, M., Jurczak, W., Jerkeman, M., Silva, R. S., Rusconi, C., Trneny, M., Offner, F., Caballero, D., Joao, C., Witzens-Harig, M., Hess, G., Bence-Bruckler, I., Cho, S-G., Bothos, J., Goldberg, J. D., Enny, C., Traina, S., Balasubramanian, S., Bandyopadhyay, N., Sun, S. & 3 andra, Vermeulen, J., Rizo, A. & Rule, S., 2016, I : The Lancet. 387, 10020, s. 770-778

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  48. No survival benefit associated with routine surveillance imaging for Hodgkin lymphoma in first remission: a Danish-Swedish population-based observational study.

    Jakobsen, L. H., Hutchings, M., de Nully Brown, P., Linderoth, J., Mylam, K. J., Molin, D., Johnsen, H. E., Bøgsted, M., Mats Jerkeman & El-Galaly, T. C., 2016, I : British Journal of Haematology.

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  49. 2015
  50. Antagonistic Human FcγRIIB (CD32B) Antibodies Have Anti-Tumor Activity and Overcome Resistance to Antibody Therapy In Vivo.

    Roghanian, A., Teige, I., Mårtensson, L., Cox, K. L., Kovacek, M., Ljungars, A., Mattson, J., Sundberg, A., Vaughan, A. T., Shah, V., Smyth, N. R., Sheth, B., Chan, H. T. C., Li, Z-C., Williams, E. L., Manfredi, G., Oldham, R. J., Mockridge, C. I., James, S. A., Dahal, L. N. & 12 andra, Hussain, K., Björn Nilsson, Verbeek, J. S., Gunnar Juliusson, Markus Hansson, Mats Jerkeman, Johnson, P. W. M., Davies, A., Beers, S. A., Glennie, M. J., Frendéus, B. & Cragg, M. S., 2015, I : Cancer Cell. 27, 4, s. 473-488

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  51. Central nervous system relapse in peripheral T-cell lymphomas: A Swedish lymphoma registry study.

    Fredrik Ellin, Landström, J., Mats Jerkeman & Relander, T., 2015, I : Blood. 126, 1, s. 36-41

    Forskningsoutput: TidskriftsbidragArtikel i vetenskaplig tidskrift

  52. Emerging role of SOX11 in mantle cell lymphoma

    Venera Kuci, Nordström, L., Mats Jerkeman & Sara Ek, 2015, I : Blood and Lymphatic Cancer: Targets and Therapy. 5, s. 35-41

    Forskningsoutput: TidskriftsbidragÖversiktsartikel

Föregående 1 2 3 Nästa